Vertex Pharmaceuticals Inc
DUS:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
DUS:VX1
|
US |
|
Norsk Hydro ASA
OTC:NHYDY
|
NO |
|
Estee Lauder Companies Inc
BMV:EL
|
US |
|
Equinor ASA
OSE:EQNR
|
NO |
|
C
|
Capita PLC
XMUN:CTAA
|
UK |
|
Aligos Therapeutics Inc
F:5WK
|
US |
Wall St Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for VX1 is 472.05 EUR with a low forecast of 281.65 EUR and a high forecast of 568.76 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
472.05
EUR
According to Wall Street analysts, the average 1-year price target for VX1 is 472.05 EUR with a low forecast of 281.65 EUR and a high forecast of 568.76 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
The compound annual growth rate for Net Income over the next 8 years is 15%.
